Your browser doesn't support javascript.
loading
The efficacy of Andrographis paniculata (Burm.f.) Wall. ex Nees crude extract in hospitalised mild COVID-19 patients: a retrospective cohort study
Jeeranan Tanwettiyanont; Napacha Piriyachananusorn; Lilit Sangsoi; Benjawan Boonsong; Chamlong Sunpapoa; Patcharawan Tanamatayarat; Sukrit Kanchanasurakit; Nat Na-Ek.
Afiliação
  • Jeeranan Tanwettiyanont; Division of Clinical Pharmacy, Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, 56000 Thailand
  • Napacha Piriyachananusorn; Division of Pharmaceutical care, Department of Pharmacy, Phrae Hospital, Phrae, 54000 Thailand
  • Lilit Sangsoi; Division of Pharmaceutical care, Department of Pharmacy, Phrae Hospital, Phrae, 54000 Thailand
  • Benjawan Boonsong; Division of Pharmaceutical care, Department of Pharmacy, Phrae Hospital, Phrae, 54000 Thailand
  • Chamlong Sunpapoa; Division of Internal Medicine, Department of Nurse, Phrae Hospital, Phrae, 54000 Thailand
  • Patcharawan Tanamatayarat; Division of Pharmacy and Technology, Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, 56000 Thailand
  • Sukrit Kanchanasurakit; Division of Clinical Pharmacy, Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, 56000 Thailand
  • Nat Na-Ek; Division of Social and Administration Pharmacy, Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, 56000 Thaila
Preprint em En | PREPRINT-MEDRXIV | ID: ppmedrxiv-22268609
ABSTRACT
BackgroundAndrographis paniculata (Burm.f.) Wall. ex Nees (AP) has been widely used in Thailand to treat mild COVID-19 infections since early 2020; however, supporting evidence is scarce and ambiguous. Thus, this study aimed to examine whether the use of AP is associated with a decreased risk of pneumonia in hospitalised mild COVID-19 patients. MethodsWe collected data between March 2020 and August 2021 from COVID-19 patients admitted to one hospital in Thailand. Patients whose infection was confirmed by real-time polymerase chain reaction, had normal chest radiography and did not receive favipiravir at admission were included and categorised as either AP (deriving from a dried and ground aerial part of the plant), given as capsules with a total daily dose of 180 mg of andrographolide for five days or standard of care. They were followed for pneumonia confirmed by chest radiography. Multiple logistic regression was used for the analysis controlling for age, sex, diabetes, hypertension, statin use, and antihypertensive drug use. ResultsA total of 605 out of 1,054 patients (mostly unvaccinated) were included in the analysis. Of these, 59 patients (9.8%) developed pneumonia during the median follow-up of 7 days. The incidence rates of pneumonia were 13.93 (95% CI 10.09, 19.23) and 12.47 (95% CI 8.21, 18.94) per 1,000 person-days in the AP and standard of care groups, respectively. Compared to the standard of care group, the odds ratios of having pneumonia in the AP group were 1.24 (95% CI 0.71, 2.16; unadjusted model) and 1.42 (95% CI 0.79, 2.55; fully adjusted model). All sensitivity analyses were consistent with the main results. ConclusionsThe use of AP was not significantly associated with a decreased risk of pneumonia in mild COVID-19 patients. While waiting for insights from ongoing trials, APs use in COVID-19 should be done with caution.
Licença
cc_by_nc
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Cohort_studies / Experimental_studies / Observational_studies / Prognostic_studies / Rct Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Cohort_studies / Experimental_studies / Observational_studies / Prognostic_studies / Rct Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint